Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy.

Hallqvist, A; Enlund, F; Andersson, C; Sjögren, H; Hussein, A; Holmberg, E; Nyman, J.

Afiliação

Hallqvist A; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 405 30 Gothenberg, Sweden ; Department of Oncology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
Enlund F; Department of Pathology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
Andersson C; Department of Pathology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
Sjögren H; Department of Cytogenetics, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
Hussein A; Department of Pathology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
Holmberg E; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 405 30 Gothenberg, Sweden.
Nyman J; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 405 30 Gothenberg, Sweden.

Lung Cancer Int ; 2012: 587424, 2012.

Article em En | MEDLINE | ID: mdl-26316935

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2012 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2012 Tipo de documento: Article